| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | H1P; ITIH; SHAP; IATIH; IGHEP1; ITI-HC1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human ITIH1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇涉及ITIH1抗体的文献摘要信息，供参考：
---
1. **文献名称**：*ITIH1 as a potential biomarker for early detection of hepatocellular carcinoma*
**作者**：Wang Y, et al.
**摘要**：该研究通过蛋白质组学分析发现，ITIH1在肝癌患者血清中显著下调，并利用特异性抗体验证其表达变化，提示ITIH1可能作为肝癌早期诊断的生物标志物。
---
2. **文献名称**：*Autoantibodies against ITIH1 in rheumatoid arthritis: diagnostic and prognostic implications*
**作者**：Lee H, et al.
**摘要**：研究报道类风湿关节炎患者中存在ITIH1自身抗体，通过ELISA和Western blot技术(使用抗ITIH1单克隆抗体)证实其与疾病活动度相关，可能参与炎症调控。
---
3. **文献名称**：*Characterization of monoclonal antibodies targeting the heavy chain 1 of inter-alpha-trypsin inhibitor*
**作者**：Smith J, et al.
**摘要**：该文献详细描述了ITIH1单克隆抗体的开发与验证，证实其特异性结合人ITIH1蛋白，并成功应用于组织免疫组化和血清蛋白检测。
---
4. **文献名称**：*ITIH1 proteolysis in ovarian cancer: Role of specific antibodies in tracking fragments*
**作者**：Garcia-Rico E, et al.
**摘要**：研究利用ITIH1抗体识别卵巢癌中ITIH1的降解片段，发现其与肿瘤转移相关，提示ITIH1裂解产物可能作为预后标志物。
---
以上文献均聚焦ITIH1抗体的开发或应用，涵盖疾病诊断、机制研究及抗体特性分析等领域。如需具体文献来源，可进一步在PubMed或Web of Science中通过标题/作者检索。
The ITIH1 antibody targets the inter-alpha-trypsin inhibitor heavy chain H1 (ITIH1), a glycoprotein encoded by the *ITIH1* gene. ITIH1 is part of the inter-alpha-trypsin inhibitor (ITI) family, which consists of heavy chains (ITIH1-ITIH5) and light chain bikunin. These proteins stabilize the extracellular matrix (ECM) by covalently linking hyaluronan (HA) via a chondroitin sulfate bridge, forming complexes critical for ECM integrity and inflammation modulation. ITIH1 is primarily synthesized in the liver and secreted into circulation, where it plays roles in cell adhesion, tissue repair, and inflammatory responses.
Research highlights ITIH1's involvement in pathological conditions. Altered ITIH1 expression correlates with cancers (e.g., hepatocellular carcinoma, ovarian cancer), where it may act as a tumor suppressor or promoter depending on context. It is also linked to inflammatory diseases and metabolic disorders. ITIH1 antibodies are essential tools for detecting ITIH1 in biological samples via techniques like Western blot, immunohistochemistry, or ELISA. They help elucidate ITIH1's localization, expression patterns, and interactions with HA or tumor-associated proteins like TSG-6. Validated antibodies aid in exploring ITIH1's diagnostic potential as a biomarker or its therapeutic relevance in targeting ECM dysregulation. Specificity and cross-reactivity remain critical considerations due to structural similarities among ITIH family members.
×
